Management

ELLIOT MAZA, JD, CPA,
CHIEF EXECUTIVE OFFICER

Elliot Maza was appointed Chief Executive Officer of Immune Pharmaceuticals in September 2017, after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015.  Previously he was Chairman, Chief Executive Officer and Chief Financial Officer at Intellect Neurosciences, Inc.,  Chief Executive Officer and Chief Financial Officer at Biozone Pharmaceuticals, Inc. and Chief Financial Officer of Emisphere Technologies Inc. Elliot was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. He began his professional career as an Attorney at Sullivan and Cromwell in New York and then in Investment banking as Vice President of Structured Finance in the Fixed Income divisions of Goldman Sachs & Co. and J.P. Morgan Securities, Inc., where he developed and marketed structured finance and derivative based transactions. Elliot has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.

 

TONY FIORINO, MD, PHD,
CHIEF MEDICAL OFFICER AND CHIEF OPERATING OFFICER


Tony joined Immune Pharmaceuticals in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ:BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.

 

JOHN MILITELLO, CPA,
VP FINANCE, CONTROLLER AND CHIEF ACCOUNTING OFFICER

John joined Immune Pharmaceuticals in April 2015 as our Executive Director of Finance and Corporate Controller. Prior to that, Mr. Militello was an Assistant Controller with Retrophin, Inc., a San Diego based biotech company, and the Manager, External Reporting & Compliance at Volt Information Sciences, Inc., a publicly traded staffing company. Prior to Volt Information Sciences, Inc., Mr. Militello was a Senior Manager with BDO USA, LLP serving multi-national SEC registrants. Mr. Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St. Joseph’s College.

 

DANIEL TEPER, PHARMD, MBA,
CHIEF EXECUTIVE OFFICER, CYTOVIA INC.

Dr. Daniel Teper is the founder Immune Pharmaceuticals and Chief Executive Officer of the company’s immuno-oncology subsidiary, Cytovia. He served as Chief Executive Officer of Immune Pharmaceuticals from its founding until April 2017. . He was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Deloitte Monitor). Daniel started his career at Novartis Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and President of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became Global President HAVAS Health, a leading marketing and communication group, where he helped launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was acquired by Japan’s Santen. Daniel holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.